EDAP Appoints Glen French to Board of Directors
EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, has appointed Glen French to its Board of Directors. French brings over 25 years of experience in medical device development and commercialization.
French's notable achievements include co-founding and selling three medical device companies and taking a fourth public. As CEO of Pulmonx (NASDAQ: LUNG), he led the company to over 20% compound annual revenue growth and a successful IPO raising $218.5 million. He previously served as President of Pulmonary Endoscopy at Boston Scientific and held CEO positions at Asthmatx and Broncus Technologies.
The appointment aims to support EDAP's strategic growth of its Focal One robotic HIFU technology platform, which targets prostate cancer treatment with potential applications in endometriosis, benign prostatic hyperplasia, and pancreatic cancer.
EDAP TMS SA (Nasdaq: EDAP), leader globale nelle terapie robotiche basate sull'energia, ha nominato Glen French nel suo Consiglio di Amministrazione. French porta con sé oltre 25 anni di esperienza nello sviluppo e nella commercializzazione di dispositivi medici.
Tra i risultati notevoli di French ci sono la co-fondazione e la vendita di tre aziende di dispositivi medici e la quotazione di una quarta. Come CEO di Pulmonx (NASDAQ: LUNG), ha guidato l'azienda a una crescita annuale composta superiore al 20% e a un'IPO di successo che ha raccolto 218,5 milioni di dollari. In precedenza, ha ricoperto il ruolo di Presidente della Endoscopia Polmonare presso Boston Scientific e ha ricoperto posizioni di CEO in Asthmatx e Broncus Technologies.
La nomina mira a supportare la crescita strategica di EDAP della sua piattaforma tecnologica Focal One HIFU robotica, che si concentra sul trattamento del cancro alla prostata con potenziali applicazioni in endometriosi, ipertrofia prostatica benigna e cancro pancreatico.
EDAP TMS SA (Nasdaq: EDAP), líder mundial en terapias robóticas basadas en energía, ha nombrado a Glen French para su Junta Directiva. French aporta más de 25 años de experiencia en el desarrollo y la comercialización de dispositivos médicos.
Entre los logros destacados de French se incluyen la co-fundación y venta de tres empresas de dispositivos médicos y llevar a una cuarta a la bolsa. Como CEO de Pulmonx (NASDAQ: LUNG), dirigió la empresa hacia un crecimiento anual compuesto superior al 20% y una exitosa OPI que recaudó 218,5 millones de dólares. Anteriormente, se desempeñó como Presidente de Endoscopia Pulmonar en Boston Scientific y ocupó puestos de CEO en Asthmatx y Broncus Technologies.
El nombramiento tiene como objetivo apoyar el crecimiento estratégico de EDAP de su plataforma tecnológica robótica Focal One HIFU, que se centra en el tratamiento del cáncer de próstata con aplicaciones potenciales en endometriosis, hiperplasia prostática benigna y cáncer de páncreas.
EDAP TMS SA (Nasdaq: EDAP)는 로봇 에너지 기반 치료의 글로벌 리더로서 글렌 프렌치를 이사회에 임명했습니다. 프렌치는 의료 기기 개발 및 상업화 분야에서 25년 이상의 경험을 가지고 있습니다.
프렌치의 주요 성과로는 세 개의 의료 기기 회사를 공동 설립하고 매각하며, 네 번째 회사를 상장한 것이 있습니다. Pulmonx (NASDAQ: LUNG)의 CEO로서 그는 회사의 연평균 수익 성장률을 20% 이상으로 이끌고, 2억 1,850만 달러를 모금하는 성공적인 IPO를 이끌었습니다. 그는 이전에 Boston Scientific의 폐 내시경 부문 사장을 역임했으며, Asthmatx와 Broncus Technologies에서 CEO로 재직했습니다.
이번 임명은 Focal One 로봇 HIFU 기술 플랫폼의 전략적 성장을 지원하기 위한 것으로, 이는 전립선암 치료에 초점을 맞추고 있으며, 자궁내막증, 양성 전립선 비대 및 췌장암에 대한 잠재적 응용이 있습니다.
EDAP TMS SA (Nasdaq: EDAP), leader mondial des thérapies robotiques basées sur l'énergie, a nommé Glen French à son conseil d'administration. French apporte plus de 25 ans d'expérience dans le développement et la commercialisation de dispositifs médicaux.
Parmi les réalisations notables de French, on trouve la co-fondation et la vente de trois entreprises de dispositifs médicaux et l'introduction en bourse d'une quatrième. En tant que PDG de Pulmonx (NASDAQ: LUNG), il a conduit l'entreprise à une croissance annuelle composée de plus de 20 % et à une introduction en bourse réussie ayant levé 218,5 millions de dollars. Auparavant, il a été président de l'endoscopie pulmonaire chez Boston Scientific et a occupé des postes de PDG chez Asthmatx et Broncus Technologies.
Cette nomination vise à soutenir la croissance stratégique d'EDAP de sa plateforme technologique Focal One HIFU robotique, qui cible le traitement du cancer de la prostate avec des applications potentielles dans l'endométriose, l'hyperplasie bénigne de la prostate et le cancer du pancréas.
EDAP TMS SA (Nasdaq: EDAP), der globale Marktführer für robotergestützte energiebasierte Therapien, hat Glen French in seinen Vorstand berufen. French bringt über 25 Jahre Erfahrung in der Entwicklung und Vermarktung von Medizinprodukten mit.
Zu Frenchs bemerkenswerten Leistungen gehören die Mitbegründung und der Verkauf von drei Medizinprodukteunternehmen sowie der Börsengang eines vierten Unternehmens. Als CEO von Pulmonx (NASDAQ: LUNG) führte er das Unternehmen zu einem jährlichen Umsatzwachstum von über 20 % und einem erfolgreichen Börsengang, bei dem 218,5 Millionen Dollar gesammelt wurden. Zuvor war er Präsident der Pulmonalen Endoskopie bei Boston Scientific und hatte CEO-Positionen bei Asthmatx und Broncus Technologies inne.
Die Ernennung zielt darauf ab, das strategische Wachstum von EDAP für die Focal One robotergestützte HIFU-Technologieplattform zu unterstützen, die sich auf die Behandlung von Prostatakrebs konzentriert und potenzielle Anwendungen bei Endometriose, benigner Prostatavergrößerung und Bauchspeicheldrüsenkrebs bietet.
- Appointment of highly experienced medical device executive with proven track record
- Board member brings expertise in successful IPOs and company scaling
- Strategic expansion potential into multiple new therapeutic areas
- Addition of leadership experienced in 20%+ revenue growth
- None.
LYON, France, March 3, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, today announced the appointment of Glen French to its Board of Directors.
“We are pleased to welcome Glen to our Board of Directors," said Dr. Lance Willsey, Interim Chairman of the Board of EDAP TMS. “Glen is a highly accomplished executive with extensive business and clinical expertise in the development of innovative new medical devices and technology, and his presence on our Board of Directors will help guide our strategic decision-making as we establish Focal One as the world’s premier robotic HIFU technology platform.”
“As a member of EDAP’s Board of Directors, I have the unique opportunity to join a company that is fundamentally changing the treatment paradigm of prostate cancer,” said Glen French. “Under its new senior leadership, EDAP has transformed itself into a high growth, world-class clinical and marketing organization that is now at the forefront of applying robotic HIFU technology to address significant unmet medical need in large patient populations. As Focal One continues to grow for the management of prostate cancer, I believe this technology can be successfully applied across several other therapeutic areas, including endometriosis, benign prostatic hyperplasia, and pancreatic cancer. I look forward to working with my fellow Board members to help realize the full potential value of EDAP’s leading Focal One platform.”
Mr. French is a highly experienced public and private medical device and technology executive with more than 25 years of experience in the development and commercialization of diagnostic and therapeutic products. He co-founded, built, and sold three medical device companies, and took a fourth company public. For nearly a decade, Glen was the CEO of Pulmonx Corporation (NASDAQ: LUNG), which develops and markets minimally invasive technologies for the diagnosis and treatment of patients with severe emphysema. During his tenure, the company executed four successful randomized controlled clinical trials, each published in world-class peer-reviewed journals, leading to inclusion in global guidelines, and broad and attractive reimbursement. Also under his leadership, Pulmonx experienced more than
Prior to Pulmonx, Glen was President, Pulmonary Endoscopy, Boston Scientific Corporation (BSC). Before BSC, he was CEO and Co-founder of Asthmatx, where he led the company from concept, through clinical studies, product launch, and acquisition by BSC. Prior to Asthmatx, Glen was CEO and Co-founder of Broncus Technologies (now Broncus Holding Corp, 2216.HK), and Director and Co-founder of NDO Surgical. Earlier in his career he held an array of sales and marketing management roles with C.R. Bard, Centocor, and American Hospital Supply Corporation.
Glen currently serves as a member of the Board of Directors of Pulmonx Corporation (NASDAQ:LUNG), Myka Labs, and CoLabs, Inc. He received a B.A. in History from Dartmouth College and an M.B.A. in Marketing and Management from The Wharton School, University of Pennsylvania.
About EDAP TMS SA
A recognized leader in robotic energy-based therapies, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various conditions using ultrasound technology. By combining the latest technologies in imaging, robotics and precise non-invasive energy delivery, EDAP TMS introduced the Focal One® in Europe and in the U.S. as the leading prostate focal therapy controlled by urologists with the potential to expand to multiple indications beyond prostate cancer. For more information on the Company, please visit https://focalone.com.
Forward-Looking Statements
In addition to historical information, this press release contains forward-looking statements within the meaning of applicable federal securities laws, including Section 27A of the U.S. Securities Act of 1933 (the “Securities Act”) or Section 21E of the U.S. Securities Exchange Act of 1934, which may be identified by words such as “believe,” “can,” “contemplate,” “could,” “plan,” “intend,” “is designed to,” “may,” “might,” “potential,” “objective,” “target,” “project,” “predict,” “forecast,” “ambition,” “guideline,” “should,” “will,” “estimate,” “expect” and “anticipate,” or the negative of these and similar expressions, which reflect our views about future events and financial performance. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties, including matters not yet known to us or not currently considered material by us, and there can be no assurance that anticipated events will occur or that the objectives set out will actually be achieved. Important factors that could cause actual results to differ materially from the results anticipated in the forward-looking statements include, among others, the clinical status and market acceptance of our HIFU devices and the continued market potential for our lithotripsy and distribution divisions, as well as risks associated with the current worldwide inflationary environment, the uncertain worldwide economic, political and financial environment, geopolitical instability, climate change and pandemics like the COVID 19 pandemic, or other public health crises, and their related impact on our business operations, including their impacts across our businesses or demand for our devices and services.
Other factors that may cause such a difference may also include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission and in particular, in the sections "Cautionary Statement on Forward-Looking Information" and "Risk Factors" in the Company's Annual Report on Form 20-F.
Forward-looking statements speak only as of the date they are made. Other than required by law, we do not undertake any obligation to update them in light of new information or future developments. These forward-looking statements are based upon information, assumptions and estimates available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete.
Company Contact
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com
Investor Contact
John Fraunces
LifeSci Advisors, LLC
(917) 355-2395
jfraunces@lifesciadvisors.com
FAQ
What experience does Glen French bring to EDAP's Board of Directors?
What are the potential expansion areas for EDAP's Focal One HIFU technology?
What was Glen French's most recent executive position before joining EDAP?
How does Glen French's appointment align with EDAP's strategic goals?
